Phaos Technology Holdings (Cayman) (POAS) Accumulated Expenses (2024 - 2025)

Phaos Technology Holdings (Cayman) (POAS) posted Accumulated Expenses of $779971.0 for Q4 2025, up 92.48% on a QoQ basis from $405231.0 in Q2 2025.

Phaos Technology Holdings (Cayman) (POAS) Accumulated Expenses (2024 - 2025) Analysis & Trends

Phaos Technology Holdings (Cayman)'s Accumulated Expenses history runs 2 years deep, the most recent figure standing at $779971.0 for Q4 2025.

Quarterly Accumulated Expenses changed N/A year-over-year to $779971.0 in Q4 2025, while the trailing twelve-month figure through Oct 2025 was $779971.0 (changed N/A YoY) and the FY2025 annual result came in at $405602.2, up 22.73% from the prior year.
Accumulated Expenses was $779971.0 for Q4 2025 at Phaos Technology Holdings (Cayman), up from $405231.0 in the prior quarter.
Across five years, Accumulated Expenses topped out at $779971.0 in Q4 2025 and bottomed at $330495.2 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	182.32 Bn	175.02 Bn	6.27 Bn
2	Stryker	128.75 Bn	125.88 Bn	3.81 Bn
3	Medtronic	107.83 Bn	98.61 Bn	6.41 Bn
4	Boston Scientific	67.61 Bn	66.15 Bn	3.61 Bn
5	Edwards Lifesciences	48.13 Bn	44.45 Bn	1.29 Bn
6	Dexcom	28.26 Bn	27.14 Bn	750.30 Mn
7	GE HealthCare Technologies	27.78 Bn	25.50 Bn	1.98 Bn
8	Smith & Nephew	26.99 Bn	26.41 Bn	-
9	Koninklijke Philips	23.92 Bn	20.80 Bn	2.07 Bn
10	Phaos Technology Holdings (Cayman)	6.05 Mn	5.99 Mn	-

Download Data